Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07743268 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS

StatusEnrolling by Invitation
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
n-Lorem Foundation
17 trials monitored
See all monitored trials
ALS
398 trials monitored
See 21 trials at risk
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
Trial Details
NCT Number NCT07743268
Lead Sponsor n-Lorem Foundation
Collaborators: Columbia University, Washington University School of Medicine
Conditions
(from sponsor)		 Amyotrophic Lateral Sclerosis (ALS)
Related terms Amyotrophic Lateral Sclerosis
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov